Chroma will provide the targets and DPI will use its comprehensive compound collection and its proprietary discovery processes and data management tools to identify potential lead compounds or potential lead series.
“Discovery Partners has impressed us with its track record in successfully screening against a diverse range of targets,” stated Ian Nicholson, CEO of Chroma Therapeutics. “The combination of its professional approach along with its extensive collection of drug-like leads provides us with confidence that we will rapidly identify novel new potential leads against our therapeutics targets.”
Chroma Therapeutics has a diversified pipeline of chromatin-based programs with the potential to deliver a totally new class of targeted cancer agents, combining the efficacy of cytotoxics with the safety and tolerability of molecular-targeted agents. The company’s lead development candidate, CHR-2797, entered phase I clinical development in November 2004.